After years in the biotech industry, Xuefei Gao began to notice a persistent gap: despite an explosion of data, the pace of drug development hadn’t meaningfully accelerated. Scientists had more tools and datasets than ever—but connecting the dots across them remained painfully slow. Gao’s experience in biotech venture investment, combined with her MBA and MPH...